New England Nuclear (LNTH) vs. The Competition Financial Survey

New England Nuclear (NASDAQ: LNTH) is one of 24 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its rivals? We will compare New England Nuclear to related companies based on the strength of its valuation, analyst recommendations, institutional ownership, dividends, profitability, risk and earnings.

Analyst Ratings

How to Become a New Pot Stock Millionaire

This is a breakdown of current ratings and price targets for New England Nuclear and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
New England Nuclear 0 1 3 0 2.75
New England Nuclear Competitors 101 367 567 19 2.48

New England Nuclear presently has a consensus target price of $24.00, indicating a potential upside of 56.35%. As a group, “Diagnostic substances” companies have a potential upside of 13.49%. Given New England Nuclear’s stronger consensus rating and higher possible upside, analysts plainly believe New England Nuclear is more favorable than its rivals.

Earnings & Valuation

This table compares New England Nuclear and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
New England Nuclear $331.38 million $123.38 million 15.35
New England Nuclear Competitors $308.35 million $18.66 million -39.62

New England Nuclear has higher revenue and earnings than its rivals. New England Nuclear is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares New England Nuclear and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
New England Nuclear 37.23% -68.13% 14.00%
New England Nuclear Competitors -884.88% -64.84% -17.51%

Volatility and Risk

New England Nuclear has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, New England Nuclear’s rivals have a beta of 1.44, suggesting that their average stock price is 44% more volatile than the S&P 500.

Institutional and Insider Ownership

90.5% of New England Nuclear shares are held by institutional investors. Comparatively, 53.6% of shares of all “Diagnostic substances” companies are held by institutional investors. 1.2% of New England Nuclear shares are held by company insiders. Comparatively, 13.5% of shares of all “Diagnostic substances” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

New England Nuclear beats its rivals on 10 of the 13 factors compared.

About New England Nuclear

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Receive News & Ratings for New England Nuclear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for New England Nuclear and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Virco Manufacturing  Getting Somewhat Favorable News Coverage, Report Finds
Virco Manufacturing Getting Somewhat Favorable News Coverage, Report Finds
Favorable Press Coverage Somewhat Unlikely to Affect Fuling Global  Share Price
Favorable Press Coverage Somewhat Unlikely to Affect Fuling Global Share Price
Head to Head Review: Southern Missouri Bancorp  and Home Bancorp
Head to Head Review: Southern Missouri Bancorp and Home Bancorp
Analyzing Yandex  and Its Competitors
Analyzing Yandex and Its Competitors
J.Jill  versus Cherokee  Head to Head Review
J.Jill versus Cherokee Head to Head Review
Insights Network Price Up 46.1% This Week
Insights Network Price Up 46.1% This Week


Leave a Reply

© 2006-2018 Ticker Report. Google+.